|
|
|
| A long-standing partner engaged JHS to explore ways to reduce cycle times for a biologic drug, aiming to serve more patients more efficiently. The case underscores how long-term partnerships and collaborative problem-solving can unlock substantial productivity gains in pharmaceutical manufacturing. By combining process expertise, operational discipline, and shared commitment to patient outcomes, JHS and its partner developed sustainable improvements that expanded production capacity and improved delivery timelines. |
|
|
|
|
CHO Cell Lines For Recombinant Protein Production | White Paper | Mabion | Discover how new strategies in CHO cell line development are driving innovation and transforming the future of biologics manufacturing, from enhanced productivity to improved therapeutic quality. |
|
|
Imaging Large Volume Subcutaneous Injections To Inform Clinical Design | Poster | By Natasha G. Bolick, Wendy D. Woodley, Suvadra S. Gerth, Douglas B. Sherman, et al., BD Medical - Pharmaceutical Systems | New higher volume, higher viscosity pharmaceutical formulations for subcutaneous injection, alternatives to traditional intravenous treatment, enable chronic disease therapy in alternate settings. |
|
|
|
|
By Louis Garguilo, chief editor, Outsourced Pharma | Most readers know the FDA embraced "radical transparency” by publishing more than 200 complete response letters (CRLs) for drug and biologics applications submitted between 2020 and 2024. Hooray for the FDA; good for drug developers hard at work today. Good for developers, writes Chief Editor Louis Garguilo, because he can identify patterns to help us outsource better. | |
|
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
|
Improving Efficiency In Contamination Identification | Case Study | AGC Biologics | Learn how rapid microbial identification using MALDI-TOF improves contamination response, shortens investigation timelines, and enhances efficiency in biopharmaceutical manufacturing. |
|
|
|
|
|
|
|
| Take a tour of Nanoform's best-in-class nanodevelopment capabilities, setting new standards in innovation. Their highly specialized team excels in creating unique nanoparticles for both small and large molecule APIs. With 14 development lines for small molecules and 5 for large molecules, Nanoform offers unmatched scalability and precision. Leveraging cutting-edge technology, they produce nanoformed materials as small as 10 nanometers. Learn more. |
|
|
|
|
|
|
|
Antibody Discovery And Engineering Services | Curia | Review a comprehensive suite of services for researchers seeking potent and functional antibodies. Find a variety of high-performance hybridoma- and display-based technologies. |
|
|
OUTSOURCED PHARMA CAPACITY UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capacities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
